ImmunityBio (IBRX) Expected to Announce Earnings on Monday

ImmunityBio (NASDAQ:IBRX) will likely be releasing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect ImmunityBio to post earnings of ($0.08) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:00 PM ET.

ImmunityBio Trading Up 1.0%

Shares of IBRX stock opened at $8.70 on Monday. The company has a market cap of $8.57 billion, a PE ratio of -21.22 and a beta of 0.14. The company’s fifty day simple moving average is $4.48 and its 200-day simple moving average is $3.12. ImmunityBio has a 52 week low of $1.83 and a 52 week high of $9.25.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on IBRX. HC Wainwright upped their price objective on shares of ImmunityBio from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. D. Boral Capital restated a “buy” rating and set a $24.00 price objective on shares of ImmunityBio in a report on Tuesday, February 17th. BTIG Research increased their target price on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, Piper Sandler raised their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, ImmunityBio has a consensus rating of “Moderate Buy” and a consensus price target of $11.80.

Trending Headlines about ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European conditional approval and EU commercialization push — the European Commission granted conditional marketing authorization for ANKTIVA® in combination with BCG for BCG‑unresponsive NMIBC CIS, and ImmunityBio is opening an Irish subsidiary and signing distribution deals (Accord) to support the EU launch, which meaningfully expands addressable market and revenue runway. ImmunityBio Expands Access to ANKTIVA® in EU (BusinessWire)
• Positive Sentiment: Regional commercial expansion — ImmunityBio struck a partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA® in Saudi Arabia and the broader MENA region, giving the drug local distribution partners and accelerating market entry in a sizeable oncology market. ImmunityBio Partners to Launch ANKTIVA in Saudi Arabia (BusinessWire)
• Positive Sentiment: Technical momentum — the stock is showing strong technicals (reported “golden cross” and trading well above the 200‑day average), reinforcing momentum traders and institutional interest. ImmunityBio Holds Golden Cross (Benzinga)
• Neutral Sentiment: Chairman commentary and publicity — public comments linking diplomatic efforts to commercial success have generated headlines and may sustain retail interest, but they are narrative-driven rather than new financial data. Chairman Comments on Diplomacy (MSN)
• Neutral Sentiment: Corporate finance/clinical updates referenced in coverage — some articles note follow‑up clinical programs and past convertible‑note activity; these are worth monitoring for dilution or R&D progress but contain no immediate financial details. Clinical/Convertible Note Context (MSN)
• Negative Sentiment: Investor litigation investigation — Pomerantz LLP announced an investigation into ImmunityBio on behalf of investors, which introduces legal and reputational risk that could pressure the stock if it leads to claims or disclosures. Pomerantz Investigates (PR Newswire)

Insider Buying and Selling at ImmunityBio

In related news, Director Barry J. Simon sold 151,967 shares of the stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $7.20, for a total value of $1,094,162.40. Following the sale, the director owned 3,091,604 shares of the company’s stock, valued at $22,259,548.80. This trade represents a 4.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christobel Selecky sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $5.00, for a total value of $250,000.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 226,967 shares of company stock valued at $1,531,912. Corporate insiders own 69.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Invesco Ltd. increased its position in shares of ImmunityBio by 14.6% in the fourth quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock worth $362,000 after acquiring an additional 23,353 shares in the last quarter. Corient Private Wealth LLC boosted its stake in ImmunityBio by 69.7% in the 4th quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock worth $660,000 after purchasing an additional 136,858 shares during the period. EP Wealth Advisors LLC purchased a new position in ImmunityBio during the 4th quarter worth approximately $35,000. Empowered Funds LLC purchased a new position in ImmunityBio during the 4th quarter worth approximately $28,000. Finally, VARCOV Co. acquired a new stake in ImmunityBio during the 4th quarter valued at $524,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.